Icon

MICARDIS (nda020850)- (20MG,40MG,80MG)

TELMISARTAN BOEHRINGER INGELHEIM
20MG,40MG,80MG
Yes No
2020-Jan-10 Expired
None None
None No
MICARDIS is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors
15 0 14
Total Other Developers 25
Drugs with Suitability No
20MG ** ** - - 10
40MG ** ** - - 10
80MG ** ** - - 10
NDA Sales Available Total Generic Sales Available
Yes 10
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ********* ** ***** ******* *********** **** ** ****, *-*** ** *-***, *-*** ** *-***, **** ** *-***/*/*/*, *-****, *-***, *-***, *-***, ***** ********** ****, ********, *** ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** ** *-*, ******* ********** ******, *******-******,, ***, ** ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ***** ****** ***** ************ ******* *********** ****** **. ***, *** & ***, ******* ***** ******** ******* ** * *, *******-*******, ***-******, ****. - *********, *********, ******* ******, ***** (***) ***
****** ****** ****** ****** *************** ** *** ****, *** *********** ** ********** **, **********, *** **** (**) *****-****, ****** ****** (***) ***
****** ****** ****** ****** *************** ******* ******* *********** ****** **.***, *** ** ***, **** ***** ********* *******-***** *******, ******* ******, *** *****, *********, ******* ******, ***** (***) ***
****** ******** ******** ********** ******* *********** **-**/*-***/*, ********** ********* ************* (****),, *****, *********** ******, ***** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ***** **** ***** **** ******* *********** **** **. *-*** ** *-*** & **, ***** *** & ***** **, ***** ********** ******, *****, *** ******, ***** (***) ***
****** ******** *** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***
****** ****** ****** *** ****** *************** ******* *********** ****, ****** ****, ******, *********, ******* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** **** **. */*** ** ***, ***** *** ****-**, ****** *****, ****. *******, *******, ******* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********-******* *******, ******, ******-****, ****. *******, ******, ******* ******, ***** (***) ***
****** ******* ****** ******* ****** ******* *********** ****-***, ******* *****, ****** **** ****, ***. ****** *******, ****** *****, *******, ******** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.